FRACTURE RISK ASSESSMENT OPTION FOR DPX SERIES BONE DENSITOMETERS

K983271 · Lunar Corp. · KGI · Nov 18, 1998 · Radiology

Device Facts

• Record ID: K983271
• Device Name: FRACTURE RISK ASSESSMENT OPTION FOR DPX SERIES BONE DENSITOMETERS
• Applicant: Lunar Corp.
• Product Code: KGI · Radiology
• Decision Date: Nov 18, 1998
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 892.1170
• Device Class: Class 2

Intended Use

The Fracture Risk option is used with the LUNAR DPX Series of bone densitometer systems. This option provides an assessment of relative fracture risk based on the patient's T-score value using the categories of fracture risk defined by the World Health Organization (WHO). Physician and patient information is provided to indicate that although bone density is the single most important factor in the assessment of fracture risk and the diagnosis of osteoporosis, the physician should also consider other factors. The use of the Fracture Risk option for DPX Series is restricted to prescription use only. The operator's manual for the DPX system contains the following statement: "United States Federal Law restricts this device to the sale, distribution, and use by or on the order of a physician."

Device Story

Software accessory for LUNAR DPX Series bone densitometers; calculates relative fracture risk based on patient T-score values; utilizes World Health Organization (WHO) risk categories. Operates as an add-on to existing densitometry examinations; does not alter scan parameters or primary density results. Used in clinical settings by physicians to aid in osteoporosis diagnosis and fracture risk assessment. Output provided to clinicians to support clinical decision-making alongside other patient factors. Benefits patients by providing standardized risk stratification based on bone mineral density data.

Clinical Evidence

No clinical data provided; bench testing only.

Technological Characteristics

Software accessory for DPX Series bone densitometers. Operates as a computational module for T-score categorization. No hardware changes to the host densitometer. Connectivity and specific algorithm architecture not detailed.

Indications for Use

Indicated for patients undergoing bone mineral density assessment via LUNAR DPX Series systems to provide relative fracture risk categorization based on WHO T-score criteria. Restricted to prescription use by physicians.

Regulatory Classification

Identification

A bone densitometer is a device intended for medical purposes to measure bone density and mineral content by x-ray or gamma ray transmission measurements through the bone and adjacent tissues. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.

Predicate Devices

• Norland-Cameron Model 178 Bone Mineral Analyzer (pre amendment)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the word "LUNAR" in bold, black letters. The font is sans-serif and appears to be a blocky, slightly rounded style. The letters are closely spaced, creating a solid visual impact.

K983271

MADISON, WI 53713 313 W. BELTLINE HIGHWAY

[phone]

### 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS 9.0

This summary of safety and effectiveness information is submitted in accordance with the requirements of 21 CFR 807.92(c).

| Contact Person: | Kenneth D. Buroker<br>LUNAR Corporation<br>313 West Beltline Highway<br>Madison, WI 53713 |
|----------------------|-------------------------------------------------------------------------------------------|
| Phone: | [phone] |
| Fax: | [phone] |
| Date: | September 15, 1998 |
| Device/Trade Name: | Fracture Risk option for DPX Series Bone Densitometers |
| Common Name: | Bone Densitometer |
| Classification Name: | Bone Densitometer<br>21CFR 892.1170 |
| Predicate Device: | Norland-Cameron Model 178 Bone Mineral Analyzer (pre amendment) |

# DESCRIPTION OF THE DEVICE: 9.1

The Fracture Risk Option for DPX Series Bone Densitometers provides fracture risk assessment based on patient's bone mineral density T-score.

# 9.2 SUMMARY OF TECHNICAL CHARACTERISTICS

The Fracture Risk option for DPX Series is a software accessory to aid the physician in assessing fracture risk from the results of a DPX Series bone density examination. The Fracture Risk Assessment Feature does not cause any changes to the scan parameters used in the examination, and it does not affect the results produced.

{1}------------------------------------------------

## 9.3 CONCLUSION

The Fracture Risk option for the DPX series bone densitometers is substantially equivalent to the Norland-Cameron Model 178 Bone Mineral Analyzer, a pre-amendment device that was used to aid the physician in determining fracture risk. No new safety and effectiveness questions are raised with the Fracture Risk option for DPX Series bone densitometers.

Signed

Kenneth D. Buroker Name

Director, Regulatory Affairs Title

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized design of three human profiles facing right, with flowing lines suggesting movement or connection. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular pattern around the central design.

Re:

Public Health Service

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

NOV 1 8 1998

Kenneth D. Buroker Director, Regulatory Affairs Lunar Corporation 313 West Beltline Highway Madison, WI 53713

K983271

Fracture Risk Assessment Option for DPX Series Bone Densitometer Dated: September 15, 1998 Received: September 17, 1998 Regulatory class: II 21 CFR 892.1170/Procode: 90 KGI

Dear Mr. Buroker:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisious of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone] or at its Internet address "http://www.fda.gov/cdr/dsmardsmamain.html".

Sincerely yours,

William Yip

Lillian Yin, Ph.D Director, Division of Reproductiv Abdominal, Ear, Nose and Thro and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

#### INDICATION FOR USE FORM 3.0

- 510(k) Number (if known) _ 1983271 .
- Device Name: Fracture Risk option for DPX Series Bone Densitometers .
- . Indications for use:

The Fracture Risk option is used with the LUNAR DPX Series of bone densitometer systems. This option provides an assessment of relative fracture risk based on the patient's T-score value using the categories of fracture risk defined by the World Health Organization (WHO). Physician and patient information is provided to indicate that although bone density is the single most important factor in the assessment of fracture risk and the diagnosis of osteoporosis, the physician should also consider other factors.

The use of the Fracture Risk option for DPX Series is restricted to prescription use only. The operator's manual for the DPX system contains the following statement:

> "United States Federal Law restricts this device to the sale, distribution, and use by or on the order of a physician."

The Fracture Risk option for DPX Series poses no new safety or efficacy concerns.

# PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED.

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use
(Per 21 CFR 801.109)

OR

Over-the-Counter Use

(Optional Format 1-2-96)

Urnid A. Seppman

(Division Sign-Off) Division of Reproductive, Abdominal, ENT and Radiological D

510(k) Number K983271